480 related articles for article (PubMed ID: 29086682)
1. Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis.
Nagel S; Streicher EM; Klopper M; Warren RM; Van Helden PD
Curr Drug Metab; 2017; 18(11):1030-1039. PubMed ID: 29086682
[TBL] [Abstract][Full Text] [Related]
2. Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens.
Rivière E; Whitfield MG; Nelen J; Heupink TH; Van Rie A
Clin Microbiol Infect; 2020 Oct; 26(10):1332-1337. PubMed ID: 32653663
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of novel
Valafar F; Ramirez-Busby SM; Torres J; Paul LV; Rodwell TC; Victor TC; Rodrigues C; Gler MT; Crudu V; Catanzaro T
Int J Mycobacteriol; 2015 Mar; 4(Suppl 1):51-52. PubMed ID: 27695670
[TBL] [Abstract][Full Text] [Related]
4. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
5. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965
[TBL] [Abstract][Full Text] [Related]
6. Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis.
Ando H; Kondo Y; Suetake T; Toyota E; Kato S; Mori T; Kirikae T
Antimicrob Agents Chemother; 2010 May; 54(5):1793-9. PubMed ID: 20211896
[TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
[TBL] [Abstract][Full Text] [Related]
8. Contribution of putative efflux pump genes to isoniazid resistance in clinical isolates of
Narang A; Giri A; Gupta S; Garima K; Bose M; Varma-Basil M
Int J Mycobacteriol; 2017; 6(2):177-183. PubMed ID: 28559521
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
Jing W; Zong Z; Tang B; Wang J; Zhang T; Wen S; Xue Y; Chu N; Zhao W; Huang H
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907179
[TBL] [Abstract][Full Text] [Related]
10. Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014.
Karo B; Kohlenberg A; Hollo V; Duarte R; Fiebig L; Jackson S; Kearns C; Ködmön C; Korzeniewska-Kosela M; Papaventsis D; Solovic I; van Soolingen D; van der Werf MJ
Euro Surveill; 2019 Mar; 24(12):. PubMed ID: 30914081
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
12. Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.
Pienaar E; Linderman JJ; Kirschner DE
PLoS One; 2018; 13(5):e0196322. PubMed ID: 29746491
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated from south-central in China.
Yu XL; Wen ZL; Chen GZ; Li R; Ding BB; Yao YF; Li Y; Wu H; Guo XK; Wang HH; Zhang SL
J Antibiot (Tokyo); 2014 Apr; 67(4):291-7. PubMed ID: 24326341
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
[TBL] [Abstract][Full Text] [Related]
16. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
[TBL] [Abstract][Full Text] [Related]
17. Molecular characteristics of rifampin and isoniazid resistant Mycobacterium tuberculosis strains from Beijing, China.
Jiao WW; Mokrousov I; Sun GZ; Li M; Liu JW; Narvskaya O; Shen AD
Chin Med J (Engl); 2007 May; 120(9):814-9. PubMed ID: 17531124
[TBL] [Abstract][Full Text] [Related]
18. Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs.
Imperiale BR; Zumárraga MJ; Di Giulio AB; Cataldi AA; Morcillo NS
Int J Tuberc Lung Dis; 2013 Aug; 17(8):1088-93. PubMed ID: 23827034
[TBL] [Abstract][Full Text] [Related]
19. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.
Cynamon MH; Zhang Y; Harpster T; Cheng S; DeStefano MS
Antimicrob Agents Chemother; 1999 Dec; 43(12):2922-4. PubMed ID: 10582883
[TBL] [Abstract][Full Text] [Related]
20. Current interest of isoniazid in the chemotherapy of tuberculosis in the light of its in vitro activity.
Ruiz P; Rodríguez-Cano F; Zerolo FJ; Casal M
Microb Drug Resist; 2003; 9(3):313-6. PubMed ID: 12959411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
